Member Info for Bazzaman

So looking at question 39 and Ashman's response, given the trading update last year was on 29th July 2024 and Croda's results this year are on 29th July 2025 then it looks a pretty good guess in my book that we will get the next trading update from Ashman on 29th July 2025 which will be in just under 8 weeks time.

Question 39:

Will there be a trading statement in July like last year?

Answer: We aim to issue a non-audited trading statement around the same time as last year after the financial year end. With the new financial resource available, this should be more than possible.

Question 44:

Why after 6 years and c£1.7m in salary are you completely unable to excite anyone into the company? 20p is an embarrassment to you and the presentation by the Dr. on Zenakine was one of the worst I’ve ever witnessed. Boring, stuttering, sighing, losing track, no energy, looked at deaths door. Shocking.

Answer: Share price movement/stagnation is driven by many factors outside our control. In our view, compared to other companies on AIM, we have been very active: we have evolved from pure research to an operational group selling product, we have made multiple acquisitions and we have launched our primary technology through a £multi-billion, multinational partner.

There were 55 questions replied to and these were updated very recently as he referred to recent events like staff changes and broker changes. Some of the questions he hid behind Cavendish. I suggest if you want to read all of the answers then check out the Q&A on the IMC webiste.

Overall the chances of getting anything meaningful from Ashman in the coming weeks is pretty low and as for Croda information roll on full year results in December 2025 because that looks most likely from his pathetic answers.

Question 2:

Zenakine is a part of several formulations containing other ingredients. Do we get our double digit royalty on the percentage of sales of the full formulation, or do we get a percentage of a percentage? If the latter, did you negotiate the split of revenues formulation by formulation or were you told it by Croda?

Answer: We cannot provide this level of information.

Question 8:

NDA QUESTIONS SUBMITTED:

Answer: Confidentiality provisions of the Licence Agreement apply for and beyond the terms of the licence. However, we won’t be prevented from notifying the market about revenues received to the extent the Company has a regulatory obligation to do so.

Question 9:

PRODUCT LAUNCH TIMELINES QUESTIONS SUBMITTED:

Answer: There are no products launched yet. Launch dates for new products are in the hands of Croda’s customers, however when we know that the first products have been launched, we will be informing the market.

Question 15:

How long before the Amsterdam launch were you aware that Croda were launching Zenakine in a space unrecognisable to your shareholders?

Answer: We have no obligations to provide those sorts of details.

Question 16:

If there was any further deals upcoming with Croda, would you do things differently regarding the power they yield over information? If so, what?

Answer: Given the successful launch of Zenakine to the industry, our two acquisitions and our improved financial position, we believe we are in a much stronger place for future negotiations.

Question 28:

RNS stated “trading continues in line with expectations in all group entities for the full year to June 2025”, there’s also it stated “creating a platform to reach profitability in the medium term” SA also mentioned Croda revenues are booked quarterly in arrears. What's the definition of medium term? As profit is a matter of opinion and cash is king, So short term, i.e. to period end of June 2025, will SBTX be cash flow positive with sufficient bunce to not require an additional funding round, especially after considering the underlying half-year cash burn and a broker forecast of period end net cash of just £300,000?

Answer: We refer you to the financial part of the investor presentation, the HY results and the Cavendish analyst note. It should be noted that current guidance does not include any royalty revenue for Zenakine™. Given the lack of visibility in these early stages on potential amounts and timing of royalty revenue for Zenakine™ and the confidentiality provisions of its agreement, the Group does not propose to initially forecast royalty revenue.

2m buy just gone through

Dustbin, if you got on my nerves then I would filter you but I quite enjoy reading your daily trash!!

Dustbin your English is appalling. 'YOUR WRONG' should be spelt 'YOU'RE WRONG'. Saying it in capitals is completely unnecessary as well.

Net, that was on 9th April following the extremely poor launch on the 8th as punters were underwhelmed with the communication. If you are happy with that level of communication then fine for you but I want more substance than that.

Dustbin, I'm not a worrier, I just have higher expectations of Ashman than you clearly do. I expect him to do his job which in my book includes keeping his shareholders informed on progress within the company. As Thomas says, where is the update on the other parts of the business? Ashman sacks his CFO, big tick, he changes broker, big tick but then continues to let himself down by hiding in his bunker, behind the so called NDA while Croda stamp all over him.

It's almost 2 months since the launch and the last time Ashman bothered to update us was 16th April IMC. Yet again his lack of communication leaves shareholders guessing what is happening. Is he just another weak AIM CEO with too high an opinion of himself?

Hi Toyin, it does make you wonder why the NDA hasn't been lifted when Croda continue to blast Zenakine across the globe.

Https://www.investorschronicle.co.uk/content/598feba3-9cf8-440b-be98-da9a6a047028

GLA

The biggest correction to TEK's SP will come as a result of any of 3 things, first Gross get's booted off the board, second Salt deal is real, third Guident IPO. With a bit of luck and the Lord's blessing it could all happen in 2025. GLA

Great half-year results with increase to dividend of 4.5p plus a special dividend of 0.5p making it 5p in total. Happy with that.

Give it a rest Billy boy, no-one rattled your cage.

Let's hope so Net, I'll be rooting for you but unfortunately his track record suggests otherwise.

Looks like the 1.5m buy may have been a fat finger as it was reversed.

That's woken up a green bin, no idea which one.

Only 8 weeks to go until 29th July when Croda and SBTX results come out. Will they tell us anything or will the NDA last until Christmas?

Anybody heard anything from our great leader? Thought not, perhaps that's why the selling continues as people are bored waiting for this so called 'Blockbuster' to break through.

1.5m buy at 7.9p and still the SP doesn't move, welcome to the AIM casino.........

Probably already posted but this was a month ago.

https://www.youtube.com/watch?v=G0MSt5F3Cy8

Be interesting to see what they present in Paris and New York this week.]

GLA